Clover Health Investments Corp
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Clover Health Investments Corp.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Price history
Chart
Interactive price chart (TradingView).
52-week range: 1.70 $ to 5.40 $ · Last price: 4.50 $ (As of: September 17, 2026)
Key figures
Key figures at a glance
Every figure we hold for this stock, grouped by topic. The question mark next to a label explains what the number means.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 09/18/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Comparison
Industry comparison
The stock alongside the largest companies in the same group. The median row is the middle value of the companies shown above — not of the whole industry.
Industry: Healthcare Plans
| Company | Market cap ($B) | P/E | EV/EBITDA | Gross Margin % | EBIT Margin % | Sales Growth (Year) % | Perf. 1Y % |
|---|---|---|---|---|---|---|---|
| Clover Health Investments Corp CLOV | 2.4 | – | -0.6 | 18.5 | 3.7 | 40.3 | 47.9 |
| UnitedHealth Group Incorporated UNH | 338.6 | 29.6 | 14.9 | 19.7 | 8.1 | 11.8 | 12.8 |
| CVS Health Corp CVS | 115.6 | 40.1 | 13.7 | 13.6 | 4.1 | 7.9 | 25.9 |
| Elevance Health Inc ELV | 89.9 | 17.7 | 0.0 | 26.0 | 5.3 | 12.6 | 37.0 |
| Cigna Corp CI | 72.8 | 11.9 | 7.7 | 9.1 | 5.5 | 11.3 | -4.8 |
| Humana Inc HUM | 46.3 | 41.8 | 0.0 | 13.7 | 4.7 | 10.1 | 43.3 |
| Centene Corp CNC | 33.1 | – | 3.9 | 11.4 | 5.1 | 19.4 | 107.6 |
| Molina Healthcare Inc MOH | 10.7 | 59.7 | 16.7 | 8.4 | 1.7 | 11.8 | 16.3 |
| Oscar Health Inc OSCR | 9.2 | – | 0.0 | 20.2 | 15.2 | 27.5 | 80.0 |
| Median of companies shown | 46.3 | 34.9 | 3.9 | 13.7 | 5.1 | 11.8 | 37.0 |
Based on the most recently reported figures. Only stocks from the same trading venue are lined up, so the market caps are counted in one currency. Compare in a chart →
Fiscal years
Annual Figures
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
Revenue, operating income and net income per fiscal year $M
Revenue Operating income Net income
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2018 | 281 | -186 | -202 | -4.81 | -153 | -55 | 211 |
| 2019 | 462 | -183 | -364 | -0.90 | -160 | 0 | 0 |
| 2020 | 673 | -93 | -136 | -0.34 | -119 | -617 | 267 |
| 2021 | 1,472 | -637 | -588 | -1.25 | -282 | 535 | 951 |
| 2022 | 1,097 | -287 | -340 | -0.71 | -204 | 357 | 809 |
| 2023 | 1,261 | -205 | -213 | -0.44 | -116 | 286 | 571 |
| 2024 | 1,371 | -46 | -43 | -0.09 | 35 | 341 | 581 |
| 2025 | 1,924 | -86 | -86 | -0.17 | -67 | 309 | 541 |
Quarters
Quarterly Figures
Each bar is one quarter, the last one is the most recent. Use the switch to step through the individual figures.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | -0.04 | – | 337 | -34.00 | -6.60 | -86 | -86 |
| 2025: Q1 | 0.00 | – | 462 | 33.30 | -0.30 | -16 | -17 |
| 2025: Q2 | -0.02 | -238.90 | 478 | 34.10 | -2.20 | 5 | 5 |
| 2025: Q3 | -0.05 | – | 497 | 50.10 | -4.90 | 12 | 11 |
| 2025: Q4 | -0.10 | – | 488 | 44.70 | -10.10 | -68 | -69 |
| 2026: Q1 | 0.05 | – | 749 | 62.00 | 3.60 | 108 | 107 |
| 2026: Q2 | 0.05 | 350.00 | 743 | 55.60 | 3.80 | 25 | 25 |
What Do These Terms Mean?
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Screening
Appears in These Scanners
This stock currently matches 18 of our scanner strategies — each hit links to the scanner.
Growth
Quality & Balance Sheet
Breakout & Setup
Momentum & Trend
- 21-EMA Trend
- Above the 50- & 200-SMA
- Gary Antonacci: Dual Momentum (Stock Adaptation)
- High ADR (≥5%)
- Mike Webster: Power Trend Leader
- Near 52-Week High
- RS Leader (≥90)
- RS New Highs
- Richard Moglen: Top Performers 3/6 Month
- Stage 2 Leader
- Stan Weinstein: Checklist
- Stan Weinstein: Stage 2
Risk & Weakness
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. Scanners marked in red are red-flag signals (risk/short scanners) — appearing there is not a seal of approval. View all scanners
Outlook
Analysts & Price Target
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Distribution of Recommendations
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 0.14 | 0.14 – 0.14 | 2,954 | 259.0% | 1 |
| 12/31/2027 | 0.15 | 0.15 – 0.15 | 3,564 | 7.1% | 1 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Valuation
What is priced in?
Instead of guessing what the stock is worth, we turn the question around: what free cash flow growth has to happen for today’s market value to add up? The assumptions behind it can be moved.
Today’s market value implies roughly 14.1% growth in free cash flow per year over ten years (assumptions: discount rate 10.0%, terminal growth 2.5%).
| Free cash flow (last twelve months) | $74.2M |
|---|---|
| Market cap | $2.38B |
| Free cash flow in year ten | $277.5M |
| Terminal value as a share of market value | 61.6% |
It shows which assumption is built into today’s price, not whether that assumption will hold. Every assumption can be changed with the sliders; the figures move with them.
A simplified model calculation — not a forecast and not a recommendation.
AI classification
AI Rating
Clover Health ist im Kern ein Medicare-Advantage-Versicherer (ein einziges berichtspflichtiges Segment: Insurance); die hauseigene KI-/Machine-Learning-Software „Clover Assistant" dient nachweislich dem operativen Kostenmanagement (Steuerung der Medizinkostenquote), ist aber keine belegte eigenständige Umsatzquelle. Die externe SaaS-Vermarktung als „Counterpart Assistant" wird in den Risikofaktoren ausdrücklich als noch nicht erfolgreicher „launch" beschrieben — daher „nutzt", nicht „verkauft".
View the full file — quotes, sources, reviewed filings
„Our proprietary software platform, Clover Assistant (licensed externally as Counterpart Assistant), supports clinical real-time decision making at the point of care by equipping the clinical with data and insights."
Unsere firmeneigene Softwareplattform Clover Assistant (extern lizenziert als Counterpart Assistant) unterstützt die klinische Echtzeit-Entscheidungsfindung am Behandlungsort, indem sie das klinische Personal mit Daten und Erkenntnissen ausstattet.
10-K · 2026-02-27 · View SEC filing
„...generate provider-focused machine learning, artificial intelligence and rules-based insights, and to drive action by surfacing the most relevant, personalized information about each patient to his or her provider."
... erzeugt auf Behandler ausgerichtete Erkenntnisse aus maschinellem Lernen, künstlicher Intelligenz und Regelwerken und stößt Handlungen an, indem sie die relevantesten, personalisierten Informationen zu jedem Patienten an dessen Behandler ausspielt.
10-K · 2026-02-27 · View SEC filing
„Our launch of Counterpart Assistant as a Software-as-a-Service (“SaaS”) product for external payors and providers serving the Medicare eligible population may not be successful, and, as a result, our business may be adversely affected."
Unsere Markteinführung von Counterpart Assistant als Software-as-a-Service-Produkt („SaaS") für externe Kostenträger und Leistungserbringer, die die Medicare-berechtigte Bevölkerung versorgen, könnte scheitern, und infolgedessen könnte unser Geschäft beeinträchtigt werden.
10-K · 2026-02-27 · View SEC filing
Filings Reviewed: 10-K 2026-02-27 · 10-Q 2026-05-08 · 10-Q 2025-11-07 · 10-Q 2025-08-08 · 10-Q 2025-05-09 · 10-K 2025-03-03
Rated on July 10, 2026 · How the Rating Is Built
Growth
Growth Score
Ten checks against the annual reports — each one passed counts a point.
- Revenue grows by more than 15% a year over three years 20.6%
- More than 10% revenue growth is expected for the coming year 14.2%
- Share count grows by less than 3% a year 2.8%
- Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") 36.8%
- Gross margin at 40% or higher and without meaningful erosion 18.5%
- Goodwill from acquisitions does not grow faster than revenue 0.0%
- Net debt below twice EBITDA 95 m net cash
- Operating cash flow covers the profits of the last three years 194 m
- Return on capital at 15% or higher, or up versus two years ago -25.8%
- Insiders hold at least 10% or are net buyers 4.4%
A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail
Quality check
AAQS
4/10The AAQS (AlleAktien Quality Score) checks 10 quality criteria on growth, profitability, and balance-sheet strength — per the methodology developed and published by AlleAktien, calculated by us from our own fundamental data. A stock counts as a quality stock from 9 out of 10 points. Where a company has a shorter listing history, we calculate over the fiscal years available (at least five).
- Sales growth 10Y > 5% 31.6%
- Exp. sales growth 3Y > 5% 36.1%
- EBIT growth 10Y > 5% –
- Exp. EBIT growth 3Y > 5% 36.1%
- Net debt < 4x EBIT –
- EBIT positive, 10Y straight 0
- Max. EBIT decline < 50% –
- Return on equity > 15% -28.0%
- ROCE > 15% -25.7%
- Expected return > 10% 32.1%
View stocks with the full AAQS score · Read the methodology at AlleAktien
Source: fundamental data
Insiders
Insider Transactions
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character.
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Sep 15, 2026 | Wai Conrad | CEO, Counterpart Health | Sell | 300,000 | 4.72 | 1,416,000 |
| Sep 15, 2026 | Soares Karen | Chief Legal Officer | Sell | 6,846 | 4.78 | 32,724 |
| Sep 15, 2026 | Reynoso Jamie L. | CEO, Medicare Advantage | Sell | 9,273 | 4.78 | 44,325 |
| Sep 14, 2026 | Oldakowski Joseph Frank | VP OF FINANCE AND CONTROLLER | Sell | 20,000 | 5.16 | 103,200 |
| Aug 17, 2026 | Thornton Joseph Clay | Interim CFO | Sell | 17,775 | 4.39 | 78,032 |
| Aug 12, 2026 | Soares Karen | Chief Legal Officer | Other | 108,695 | 0.00 | – |
| Aug 12, 2026 | Thornton Joseph Clay | Interim CFO | Other | 54,347 | 0.00 | – |
| Aug 10, 2026 | Toy Andrew | Chief Executive Officer | Sell | 87,798 | 4.65 | 408,261 |
| Jul 20, 2026 | Soares Karen | Chief Legal Officer | Sell | 51,700 | 4.51 | 233,167 |
| Jul 17, 2026 | Reynoso Jamie L. | CEO, Medicare Advantage | Sell | 4,839 | 4.53 | 21,921 |
The company
About the Company
Clover Health Investments, Corp. bietet Medicare-Advantage-Pläne in den USA an.
- CEO Insider Trades (12 Mo.)
- selling own stock
- Employees
- 724
- Headquarters
- Wilmington, DE
- Address
- 1209 Orange Street, 19801 Wilmington, United States
- Phone
- 201 432 2133
- Website
- cloverhealth.com
- IPO Date
- 01/02/2001
- ISIN
- US18914F1030
Management
| Name | Title | Birth Year |
|---|---|---|
| Vivek Garipalli | Co-Founder & Executive Chairman | 1979 |
| Andrew Toy | Co-Founder, CEO & Director | 1979 |
| Jamie L. Reynoso | Chief Executive Officer of Medicare Advantage | 1969 |
| Conrad Wai | CEO of Counterpart Health | 1981 |
| Clay Thornton | Interim Chief Financial Officer | 1990 |
| Joseph Frank Oldakowski | VP of Finance, Controller & Principal Accounting Officer | 1983 |
| Wendy Richey | Chief Compliance Officer | – |
| Karen Soares | Chief Legal Officer, General Counsel, Senior VP & Corporate Secretary | 1978 |
| Rachel Fish | Chief People Officer | – |
| Kumar Dharmarajan | Chief Medical Officer of Clover Assistant | 1980 |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Filings
Company Filings (8-K)
An 8-K is the filing a US company must use to disclose material events immediately — takeovers, changes at the top, major contracts or payment troubles, for instance. The links open the original document at the US Securities and Exchange Commission (SEC).
- 08/20/2026 CLOVER HEALTH INVESTMENTS, CORP. /DE (CLOV): Regulation FD Disclosure; Financial Statements and Exhibits SEC ↗
- 08/05/2026 CLOVER HEALTH INVESTMENTS, CORP. /DE (CLOV): Results of Operations and Financial Condition; Financial Statements and Exhibits SEC ↗
- 07/17/2026 CLOVER HEALTH INVESTMENTS, CORP. /DE (CLOV): Other Events SEC ↗
Data as of: September 17, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.